Uterine Sarcoma
~Introduction
Uterine sarcoma is a rare but highly aggressive group of malignant tumors that arise from the mesenchymal (connective tissue) components of the uterus, such as the myometrium, endometrial stroma, or supporting tissues. Unlike the more common endometrial carcinomas that originate from the glandular lining of the uterus, uterine sarcomas develop from muscle, stromal, or fibrous tissues. Although they account for only 3–7% of all uterine malignancies, uterine sarcomas contribute disproportionately to uterine cancer-related mortality due to their rapid growth, early metastasis, and poor prognosis.
Uterine sarcomas often present diagnostic challenges because their symptoms closely resemble benign uterine conditions such as leiomyomas (fibroids). Consequently, diagnosis is frequently made post-surgery, underscoring the need for heightened clinical suspicion and improved diagnostic strategies.
~Epidemiology
Uterine sarcomas are rare malignancies with an estimated annual incidence of 1–2 cases per 100,000 women worldwide. They predominantly affect women in the peri-menopausal and post-menopausal age group, typically between 40 and 60 years of age. However, certain subtypes, such as low-grade endometrial stromal sarcoma, may occur in younger women.
Risk Factors
Prior pelvic irradiation
Prolonged tamoxifen therapy
Rapidly enlarging uterine mass, especially after menopause
History of hereditary cancer syndromes (rare)
Obesity and nulliparity (less clearly defined)
~Classification of Uterine Sarcoma
The World Health Organization (WHO) classifies uterine sarcomas into several histological subtypes based on tissue origin:
1. Leiomyosarcoma (LMS)
Arises from the smooth muscle of the myometrium
Most common subtype
Highly aggressive with early hematogenous spread
Poor prognosis
2. Endometrial Stromal Sarcoma (ESS)
Divided into:
Low-grade ESS – indolent but recurrent
High-grade ESS – aggressive with poor outcome
3. Undifferentiated Uterine Sarcoma (UUS)
Highly malignant
Lacks specific differentiation
Very poor prognosis
4. Adenosarcoma
Mixed tumor with benign epithelial and malignant stromal components
Generally low grade but may become aggressive with sarcomatous overgrowth
~Pathogenesis
Uterine sarcomas arise due to genetic and molecular alterations affecting mesenchymal cells. These tumors often show:
Mutations in TP53, RB1, ATRX
Chromosomal rearrangements (especially in ESS)
Hormone receptor positivity (ER/PR) in low-grade ESS
Unlike benign fibroids, sarcomas exhibit uncontrolled cellular proliferation, high mitotic activity, and invasive growth patterns.
~Clinical Features
The clinical presentation of uterine sarcoma is often nonspecific, leading to delays in diagnosis.
Common Symptoms
Abnormal uterine bleeding (most common)
Post-menopausal bleeding
Pelvic or lower abdominal pain
Rapidly enlarging uterine mass
Pressure symptoms on bladder or bowel
Fatigue and weight loss (advanced disease)
Signs
Enlarged, irregular uterus
Pelvic mass
Ascites (late stage)
~Diagnostic Evaluation
1. Imaging Studies
Ultrasound: Heterogeneous uterine mass with irregular margins
MRI: Preferred modality for soft tissue differentiation; shows necrosis and hemorrhage
CT scan: Used for staging and detection of metastasis
2. Endometrial Sampling
Often non-diagnostic
Useful in cases involving endometrial stromal tumors
3. Histopathology
Definitive diagnosis is made by:
High mitotic index
Cellular atypia
Tumor necrosis
Immunohistochemistry (desmin, SMA, CD10)
~Staging of Uterine Sarcoma (FIGO)
Stage I
Tumor confined to uterus
Stage II
Extension to pelvis
Stage III
Invasion into abdominal tissues
Stage IV
Invasion of bladder or rectum or distant metastasis (lungs, liver, bone)
~Management of Uterine Sarcoma
1. Surgical Management
Total abdominal hysterectomy (TAH) is the cornerstone of treatment.
Bilateral salpingo-oophorectomy (BSO) is often performed
Lymphadenectomy is not routinely indicated
Tumor morcellation must be avoided
2. Radiotherapy
Used as adjuvant therapy
Reduces local recurrence
Does not significantly improve overall survival
3. Chemotherapy
Indicated in high-grade tumors or advanced disease
Common agents:
Doxorubicin
Ifosfamide
Gemcitabine + Docetaxel
4. Hormonal Therapy
Effective in low-grade ESS
Progestins, aromatase inhibitors, GnRH analogs
~Prognosis
Prognosis depends on:
Tumor subtype
Stage at diagnosis
Mitotic activity
Completeness of surgical excision
5-Year Survival Rates
Leiomyosarcoma: 25–40%
Low-grade ESS: 80–90%
High-grade sarcoma: <30%
~Recurrence and Metastasis
Uterine sarcomas have a high recurrence rate, often involving:
Lungs (most common)
Liver
Bone
Peritoneum
Long-term follow-up is essential due to late recurrences, especially in ESS.
~Differential Diagnosis
Leiomyoma
Endometrial carcinoma
Adenomyosis
Ovarian malignancy
~Prevention and Screening
Currently, there is no effective screening method for uterine sarcoma due to its rarity and nonspecific presentation. Early diagnosis relies on:
High clinical suspicion
Avoiding morcellation
Histopathological evaluation of suspicious masses
~Recent Advances
Molecular profiling for targeted therapy
Immunotherapy under clinical trials
Improved imaging techniques
Personalized treatment approaches
~Conclusion
Uterine sarcoma is a rare but aggressive malignancy with significant diagnostic and therapeutic challenges. Early recognition, appropriate surgical management, and tailored adjuvant therapy are crucial in improving outcomes. Due to its aggressive nature and high recurrence rate, uterine sarcoma requires multidisciplinary management and long-term follow-up. Continued research into molecular pathways and targeted therapies holds promise for improved survival and quality of life in affected patients.
No comments:
Post a Comment